Skip to main content
. Author manuscript; available in PMC: 2010 Oct 25.
Published in final edited form as: Gastroenterology. 1987 Oct;93(4):681–686. doi: 10.1016/0016-5085(87)90428-8

Table 1.

Plasma Hormone Levels in Control Rats and in Rats Treated With Spironolactone and Potassium Canrenoate

Control group 1 Spironolactone group 2 pa Potassium canrenoate group 3 pa
Testosterone (ng/ml) 1.8 ± 0.32 0.80 ± 0.24 <0.05 1.5 ± 0.30 NS
Estradiol (pg/ml) 9.8 ± 1.2 7.9 ± 2.1 NS 9.6 ± 1.1 NS
Estriol (ng/ml) 1.26 ± 0.48 1.68 ± 0.69 NS 1.18 ± 0.39 NS
Progesterone (ng/ml) 3.93 ± 0.27 3.21 ± 0.53 NS 2.71 ± 0.38 <0.05
DHEAS (ng/ml) 99.60 ± 22.3 105.0 ± 22.4 NS 38.6 ± 15.3 <0.05
FSH (mU/ml) 1.75 ± 0.34 2.46 ± 0.37 NS 1.19 ± 0.25 NS
PRL (mU/ml) 7.02 ± 0.77 6.8 ± 0.3 NS 5.95 ± 0.60 NS
LH (mU/ml) 6.52 ± 1.02 4.76 ± 0.8 NS 4.93 ± 0.93 NS

DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; NS, not significant; PRL, prolactin. Group 1 was treated with vehicle. The other groups received spironolactone (group 2) and potassium canrenoate (group 3) at the dosage of 5 mg/day for 21 days. Values are expressed as mean ± SD.

a

Values that differ from control values.